Biochemical effects of intraoperative cell salvage and autotransfusion during cesarean section: A prospective pilot study

J Obstet Gynaecol Res. 2021 May;47(5):1743-1750. doi: 10.1111/jog.14738. Epub 2021 Mar 14.

Abstract

Aim: Intraoperative cell salvage and autotransfusion (ICSA) is a useful technique for women undergoing cesarean sections who are predicted to experience significant bleeding. This method can reduce allogeneic transfusions as well as its associated risks and costs. Amniotic fluid embolism (AFE) is an abnormal maternal response to ICSA similar to the classic systemic inflammatory response syndrome, but its mechanism is not well understood. This study was conducted to investigate the biochemical aspects of AFE.

Methods: A prospective case-controlled pilot study was conducted in a general perinatal hospital in Japan. ICSA was performed using a two-step retransfusion process. Blood samples were collected presurgery, immediately postsurgery, and 24 h after surgery. Changes in sialyl Tn antigen (STN), complement C3 and C4, fibrinogen, and fibrin degradation product and D-dimer, C1 esterase inhibitor, and interleukin-8 (all considered AFE-related markers) activities were compared between patients who underwent cesarean sections with ICSA (ICSA group) versus without ICSA (control group).

Results: Fibrinogen levels were significantly lower in the ICSA group than in the control group before surgery but not immediately after or 24 h after surgery. D-dimer was significantly higher immediately after surgery but not 24 h later. STN was significantly lower only before surgery. None of the AFE-related markers showed significant differences between the groups after 24 h. No adverse events were observed in the ICSA group.

Conclusions: There is no clinical evidence that ICSA alters the biochemical statuses of AFE-related markers in a manner that could lead to adverse maternal responses.

Keywords: amniotic fluid embolism; autotransfusion; biochemical marker; disseminated intravascular coagulation; intraoperative cell salvage.

MeSH terms

  • Blood Transfusion, Autologous
  • Case-Control Studies
  • Cesarean Section* / adverse effects
  • Embolism, Amniotic Fluid*
  • Female
  • Humans
  • Japan
  • Pilot Projects
  • Pregnancy
  • Prospective Studies

Grants and funding